Literature DB >> 12457389

Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia.

Lisa J Phillips1, Alison R Yung, Hok Pan Yuen, Christos Pantelis, Patrick D McGorry.   

Abstract

The treatment of psychotic disorders, particularly schizophrenia, had been viewed with pessimism until a recent shift in focus from established or chronic illness to earlier phases of illness around the onset highlighted opportunities for enhanced recovery. Associated with this change in focus of research and clinical efforts has been the recognition that the biological and social changes underpinning the development of psychotic disorders may already be active in the pre-psychotic or prodromal phase. It has therefore been suggested that efforts toward the prevention of psychotic disorders should focus on the emerging illness. This article provides a review of work that has been conducted at the PACE Clinic in Melbourne, Australia since 1994. This clinical research program was established to develop strategies for the identification of young people at high risk of developing a psychotic disorder within a short period of time- primarily by virtue of recent mental state changes. Additionally, biological and psychological processes that have been proposed to underlie the development of illness have been investigated and potential preventive interventions have been evaluated. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12457389     DOI: 10.1002/ajmg.b.10790

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  13 in total

Review 1.  How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia?

Authors:  Katherine Seeber; Kristin S Cadenhead
Journal:  Curr Psychiatry Rep       Date:  2005-03       Impact factor: 5.285

Review 2.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 3.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 4.  Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.

Authors:  Randal G Ross; Robert Freedman
Journal:  Schizophr Bull       Date:  2015-05-04       Impact factor: 9.306

5.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

6.  Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study.

Authors:  P Brambilla; C Perlini; P Rajagopalan; P Saharan; G Rambaldelli; M Bellani; N Dusi; R Cerini; R Pozzi Mucelli; M Tansella; P M Thompson
Journal:  Br J Psychiatry       Date:  2013-01       Impact factor: 9.319

7.  The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex.

Authors:  Susanna Pietropaolo; Philipp Singer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2008-03-04       Impact factor: 4.530

8.  Evidence map of prevention and treatment interventions for depression in young people.

Authors:  Patrick Callahan; Ping Liu; Rosemary Purcell; Alexandra G Parker; Sarah E Hetrick
Journal:  Depress Res Treat       Date:  2012-03-15

9.  Interventions for prodromal stage of psychosis.

Authors:  Dina Bosnjak Kuharic; Ivana Kekin; Joanne Hew; Martina Rojnic Kuzman; Livia Puljak
Journal:  Cochrane Database Syst Rev       Date:  2019-11-01

10.  Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia.

Authors:  Christopher Jones; David Hacker; Jun Xia; Alan Meaden; Claire B Irving; Sai Zhao; Jue Chen; Chunhu Shi
Journal:  Cochrane Database Syst Rev       Date:  2018-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.